Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 14/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 11/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PKLR | P30613 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969742 | 0.88 | GAA (0.56) | GAASMN1; SMN2HTTKMT2ANPSR1 | |
| SCHEMBL1967740 | 0.83 | ALDH1A1 (0.58) | GAASMN1; SMN2HTTTDP1TP53 | |
| SCHEMBL15152557 | 0.80 | GAA (0.60) | GAASMN1; SMN2HTTKMT2ANPSR1 | |
| SCHEMBL15152576 | 0.80 | GAA (0.48) | GAASMN1; SMN2HTTKMT2ANPSR1 | |
| SCHEMBL1967220 | 0.80 | GAA (0.74) | GAASMN1; SMN2HTTKMT2ANPSR1 | |
| SCHEMBL2986228 | 0.78 | GAA (0.59) | GAASMN1; SMN2HTTKMT2ANPSR1 | |
| SCHEMBL2989284 | 0.78 | GAA (0.59) | GAASMN1; SMN2HTTKMT2ANPSR1 | |
| SCHEMBL1987906 | 0.78 | TRPA1 (0.42) | GAASMN1; SMN2HTTKMT2ANPSR1 | |
| SCHEMBL2984318 | 0.76 | GAA (0.57) | GAASMN1; SMN2HTTKMT2ANPSR1 | |
| SCHEMBL2738311 | 0.75 | ALDH1A1 (0.55) | GAASMN1; SMN2TP53ALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | claimed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| EP-2334675-B1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2014-03-26 | — | — | EP | disclosed |
| US-8501767-B2 | Imidazopyridines and imidazopyrimidines as HIV-1 reverse transcriptase inhibitors | CSIR (ZA) | 2013-08-06 | — | — | US | disclosed |
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-12-22 | — | — | US | disclosed |
| EP-2334675-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2011-06-22 | — | — | EP | disclosed |
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | disclosed |
| WO-2010032195-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | CSIR (ZA) | 2010-03-25 | — | — | WO | disclosed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312957-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRIMIDINES AS HIV-I REVERSE TRANSCRIPTASE INHIBITORS | TYMP, IMPDH1, DPYD | GAA 441/4885SMN1; SMN2 3745/4885HTT 4474/4885 |
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | GAA 820/4885SMN1; SMN2 46/4885HTT 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.